Light Obscuration (LO)

Light Obscuration (LO) is the primary compendial method for counting sub-visible particles (SVPs) in injectable drugs. The purpose of this test is to ensure that parenteral products meet the strict regulatory limits for particulate matter, a critical requirement for patient safety.

Harmonized across USP <788>, Ph. Eur. 2.9.19, and JP 6.07 under the Pharmacopoeial Discussion Group (PDG).

Legacy: Before automated counters, Membrane Microscopy was the standard. This involved filtering a product and manually counting particles under a microscope—a very slow and laborious process. It is still the official USP Method 2.

Current Standard: LO is the primary compendial standard (USP <788> Method 1) for sub-visible particle counting. While mandated for QC release, it is complemented by orthogonal techniques for particle characterization.

Future: LO will remain the standard for QC release counting. However, it is increasingly complemented by orthogonal techniques like Flow Imaging Microscopy (FIM), which is used for characterization to understand what the particles are, not just how many exist.

The principle of LO is straightforward and based on a light-blocking event.

• Sample Flow: A precise volume of the liquid sample is passed through a narrow sensor.
• Detection Zone: A laser beam is directed across the sensor's path and onto a photodetector.
• Obscuration Event: As a particle flows through the sensor, it blocks (or obscures) a portion of the laser beam.
• Signal Generation: The detector registers this blockage as a temporary drop in light intensity, which generates a voltage pulse.

Sizing & Counting:

• The number of pulses is equal to the number of particles.
• The height of the pulse is proportional to the size of the particle (its cross-sectional area). The instrument reports this as an "equivalent spherical diameter.

• Data Output: The instrument generates a report listing the cumulative number of particles per mL (or per container) at the compendial size thresholds: ≥ 10 µm and ≥ 25 µm.
• Interpretation: The results are compared directly to the acceptance criteria in the relevant pharmacopeia (e.g., USP <788>). For most products in containers ≤ 100 mL, the limits are:
• Not more than 6000 particles per container that are ≥ 10 µm.
• Not more than 600 particles per container that are ≥ 25 µm.
  If the sample counts are below these limits, the batch passes.

• Fast and Automated: Analyzes a sample in minutes.
• Highly Reproducible: Provides consistent and statistically robust data.
• Compendial Method: Globally accepted by regulatory agencies for product release.
• Commercial LO systems can detect particles as small as ~2 µm, but pharmacopeial acceptance criteria are specified only at ≥10 µm and ≥25 µm.

• No Morphological Information: It cannot tell the difference between a protein aggregate, a silicone oil droplet, or a fiber. It just gives a size and a count.
• Inaccuracy with Translucent Particles: Can under-count transparent particles (like some protein aggregates) because they don't block enough light.
• Prone to Artifacts: Erroneously high counts can be caused by air bubbles or silicone oil droplets if samples are not handled properly.
• Viscosity Limits: Not suitable for highly viscous or opaque solutions without dilution.

• Calibration: The instrument must be routinely calibrated for size and count accuracy using NIST-traceable standards.
• Sample Volume & Flow Rate: These parameters must be optimized and validated for each product.
• System Suitability: A "blank" measurement is run before analysis to ensure the sensor is clean and the system is ready.
• Sample Handling: Procedures for de-gassing samples (to remove air bubbles) and proper mixing are critical.

• NIST-traceable polystyrene beads of known sizes (e.g., 10 µm and 25 µm) are the essential reference materials used to calibrate the instrument.
• Count standards with a known concentration of beads are used to verify counting accuracy.

LO testing is required for most parenteral products, with specific modalities (e.g., ophthalmics under USP <789>) addressed separately.

• Monoclonal Antibodies (mAbs) & Biologics
• Small Molecule Parenterals
• Vaccines
• Cell & Gene Therapy Products
• mRNA Therapeutics (LNP formulations)